RVNC committed to disclose to investors via press release when the FDA has scheduled an inspection of RVNC’s Daxi manufacturing site in Newark, CA. This is a new policy based on the undue length of the delay from the PDUFA date in Nov 2020.
2Q21 dermal-filler sales of $17.0M were up strongly from $11.6M in 1Q21 (#msg-163715321), due partly to seasonality.
2Q21 cash operating expenses of $80.0M were higher than the quarterly rate implied by RVNC’s prior full-year guidance (excluding product sales and other revenue) of $270-285M; nevertheless, RVNC re-iterated the $270-285M guidance in today’s PR.
The 6/30/21 cash balance of $336.3M was down $50.5M from 6/30/21.
RVNC apparently did not utilize the ATM facility to a material degree during 2Q21.
News 
Market Data 
Discover 
